Rxsight, Inc. (RXST)
NASDAQ:RXST
Want to see RXST full AI Analyst Report?
RXST Stock Chart & Stats
$7.61
-$1.16(-3.26%)
At close: 4:00 PM EST
$7.61
-$1.16(-3.26%)
Day’s Range― - ―
52-Week Range$4.48 - $14.34
Previous CloseN/A
Volume110.15K
Average Volume (3M)877.27K
Market Cap
$194.98M
Enterprise Value$213.90M
Total Cash (Recent Filing)$217.88M
Total Debt (Recent Filing)$10.83M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 10, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding41,396,610
10 Day Avg. Volume1,104,341
30 Day Avg. Volume877,266
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)1.56
Price to Sales (P/S)3.19
P/FCF Ratio-22.18
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue1.68
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda-4.95
Forecast
1Y Price Target
$9.67Price Target Upside27.03% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-1.42
Revenue Forecast (FY)$129.25M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high product-level gross margins driven by LAL unit mix indicate durable economics: the implant and procedure consumables generate outsized margin per procedure. As procedural adoption and LDD utilization scale, high gross margins support eventual operating leverage and long-term profitability.
Conservative, Low Leverage Balance SheetVery low financial leverage and substantial equity provide balance-sheet flexibility to fund continued commercialization, absorb near-term cash burn, and invest in international expansion or R&D without immediate refinancing risk, preserving optionality during growth execution.
Clinical Adoption And DifferentiationAchieving 300,000 implants reflects meaningful clinical traction and real-world adoption, reinforcing the LAL’s differentiation. Strong clinician preference and demonstrated outcomes can create durable competitive advantages, aiding referral growth, training momentum, and longer-term platform stickiness.
Bears Say
Persistent Negative Cash FlowOngoing negative operating and free cash flow means the business is not yet self-funding; continued cash burn risks future dilution or the need for external capital. This constrains the pace of commercial investment and could pressure management to prioritize near-term cash metrics over long-term growth initiatives.
Weak LDD Capital PlacementsLow quarterly placements of the light delivery device slow expansion of the installed base that drives recurring adjustments and consumable revenue. LDD placement variability makes revenue lumpy, delays network effects from clinics adopting full LAL workflows, and weakens conversion of clinical interest into durable recurring revenue.
Margin Pressure And Elevated Operating ExpensesManagement expects margin headwinds from higher-cost inventory plus elevated SG&A and R&D investment this year. Together, inventory flow-through and sizable OpEx guidance compress near-term operating leverage, extending the timeline to sustained profitability even if revenue stabilizes.
RxSight News
RXST FAQ
What was Rxsight, Inc.’s price range in the past 12 months?
Rxsight, Inc. lowest stock price was $4.48 and its highest was $14.34 in the past 12 months.
What is Rxsight, Inc.’s market cap?
Rxsight, Inc.’s market cap is $194.98M.
When is Rxsight, Inc.’s upcoming earnings report date?
Rxsight, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 55 days.
How were Rxsight, Inc.’s earnings last quarter?
Rxsight, Inc. released its earnings results on May 06, 2026. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.081.
Is Rxsight, Inc. overvalued?
According to Wall Street analysts Rxsight, Inc.’s price is currently Undervalued.
Does Rxsight, Inc. pay dividends?
Rxsight, Inc. does not currently pay dividends.
What is Rxsight, Inc.’s EPS estimate?
Rxsight, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Rxsight, Inc. have?
Rxsight, Inc. has 41,396,610 shares outstanding.
What happened to Rxsight, Inc.’s price movement after its last earnings report?
Rxsight, Inc. reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went down -14.454%.
Which hedge fund is a major shareholder of Rxsight, Inc.?
Currently, no hedge funds are holding shares in RXST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.67 (27.03% Upside)
$9.67 (27.03% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 148.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 11.8%
Last 30 Days ▼ 11.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.99%
12-Months-Change
Fundamentals
Return on Equity
-17.01%
Trailing 12-Months
Asset Growth
-2.89%
Trailing 12-Months
Company Description
Rxsight, Inc.
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
RXST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: operational positives include stabilized LAL procedure volumes, improved gross margin in Q1, a major commercial milestone (300,000 implants), early signs of success from customer reengagement programs, and maintained full-year revenue guidance. Offsetting these are sizable near-term challenges — an 18% YoY revenue decline, weak LDD capital placements (only 20 sold), a Q1 net loss of $15.9M, increased SG&A/OpEx investments, and anticipated margin pressure from higher-cost inventory that will weigh on near-term profitability. Management projects gradual sequential improvement and is investing to drive longer-term growth, but near-term financial headwinds and modest 2026 volume expectations temper the outlook.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$9.67
▲(27.03% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
3.54% Insiders
14.10% Mutual Funds
23.90% Other Institutional Investors
41.54% Public Companies and
Individual Investors